Answers are grounded in this paper and cite their sources.
Introduction: Piperacillin-tazobactam (PTZ), although contested, is frequently utilized for empirical treatment of Gramnegative bacteria treatment.Objective: Systematic review to evaluate if PTZ is associated with lower rates of treatment failure and less adverse effects than other comparators. Material and Methods:Literature search in Embase, and MEDLINE databases using "piperacillin tazobactam" as leading term.A study qualified, when a properly randomized control trial (RCT) compared the efficacy and safety of PTZ with other antibacterial agents in an "intention to treat analysis" of clinically evaluable patients.Results: Eleven studies fulfilled inclusion criteria.Pooled RR of failure risk rate was 25% less using PTZ than other comparators (0.75; CI 95% 0.59-0.95).Adverse effects were similar.Conclusions: PTZ can be adequately considered for empirical treatment of patients with Gram-negative bacteria infections
No takes yet. Share an insight, caveat, or question.
Rosanova Maria Teresa (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: